Trials / Completed
CompletedNCT04308681
A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of the Efficacy and the Safety and Tolerability of BMS-986278 in Participants With Pulmonary Fibrosis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 403 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 21 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to provide an initial evaluation of the effectiveness of BMS-986278 in participants with lung fibrosis, to demonstrate the safety of BMS-986278, and provide information on the drug levels of BMS-986278 in these participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | BMS-986278 Placebo | Specified Dose on Specified Days |
| DRUG | BMS-986278 | Specified Dose on Specified Days |
Timeline
- Start date
- 2020-07-29
- Primary completion
- 2022-08-04
- Completion
- 2023-09-22
- First posted
- 2020-03-16
- Last updated
- 2026-02-03
- Results posted
- 2025-02-24
Locations
119 sites across 18 countries: United States, Argentina, Australia, Belgium, Brazil, Canada, Chile, China, France, Germany, Israel, Italy, Japan, Mexico, South Korea, Spain, Taiwan, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04308681. Inclusion in this directory is not an endorsement.